OR WAIT null SECS
June 17, 2015.
While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the early stages, according to GBI Research. This means a significant proportion of therapies are unlikely to reach the market in the near future
The report, Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation, states that 58% of drugs in the pancreatic cancer treatment pipeline are in the discovery or preclinical stages, 17% are in Phase I and 21% are in Phase II, leaving just 4% of products in Phase III of development.
The report adds that while the current global treatment market for pancreatic cancer is comprised of 91% small molecules and 9% biologics, some 41% of the pipeline is formed from biologic therapies.